DaVita Inc. (NYSE:DVA) Shares Acquired by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV lifted its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 21.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,404 shares of the company's stock after buying an additional 2,212 shares during the period. Mercer Global Advisors Inc. ADV's holdings in DaVita were worth $1,855,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DVA. Epoch Investment Partners Inc. purchased a new position in shares of DaVita in the 4th quarter valued at approximately $55,100,000. Invesco Ltd. increased its stake in DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after buying an additional 275,284 shares during the period. Amundi raised its position in DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after buying an additional 240,126 shares during the last quarter. Bridgewater Associates LP lifted its stake in shares of DaVita by 298.4% in the 4th quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock worth $35,888,000 after acquiring an additional 179,744 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of DaVita by 256.8% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock valued at $24,301,000 after acquiring an additional 116,758 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Barclays lifted their price target on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $166.33.

DaVita Price Performance

Shares of DVA traded down $3.50 on Tuesday, reaching $140.93. The stock had a trading volume of 914,279 shares, compared to its average volume of 821,348. The firm has a 50-day moving average of $145.93 and a 200 day moving average of $153.74. The firm has a market capitalization of $10.83 billion, a PE ratio of 13.12, a PEG ratio of 1.07 and a beta of 1.14. DaVita Inc. has a twelve month low of $131.44 and a twelve month high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same quarter in the prior year, the company earned $2.26 earnings per share. DaVita's revenue was up 5.0% compared to the same quarter last year. Sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.